Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)
Status:
Not yet recruiting
Trial end date:
2027-10-15
Target enrollment:
Participant gender:
Summary
This is a 3-part, Phase 3 study consisting of a dose-escalating period (DEP) of up to 15
weeks (Part 1), followed by a 4-week, double-blind, placebo-controlled randomized withdrawal
period (RWP) (Part 2), and an open-label extension (OLE) (Part 3) of up to 36 months.